Melatonin (Slenyto®) recommended as option for use within NHS Wales

This is recommended for the treatment of insomnia in children and adolescents aged 2 to 18 years with autism spectrum disorder and/or Smith-Magenis syndrome, where sleep hygiene measures have been insufficient.

All Wales Medicines Strategy Group